; Juniper Pharmaceuticals | Press Releases

Press Releases

2017 | 2016 | 2015 | 2014 | 2013

Juniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results

Revenue from Core Business Increased 17% Year-over-Year Plan to File Three INDs in the First Half of 2018 Remains on Track Conference Call at 8:30 a.m. EST Today BOSTON, March 7, 2017 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's healt...

Read More

Juniper Pharmaceuticals to Present at ROTH Conference on March 14, 2017

BOSTON, March 6, 2017 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), announced today that Alicia Secor, President and Chief Executive Officer, will present at the 29th Annual ROTH Conference as follows:   ...

Read More

Juniper Pharmaceuticals to Report Fourth Quarter and Year-End 2016 Results on March 7, 2017

-- Conference Call Scheduled for 8:30 a.m. EST -- BOSTON, March 1, 2017 /PRNewswire/ -- The management team of Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), will hold a conference call on March 7, 2017, to discuss the financial results for the fourth quarter and twel...

Read More

Juniper Pharmaceuticals Presents Poster at SMFM 2017 on Current Practice Among U.S. Obstetricians to Screen, Define, and Treat a Short Cervix to Prevent Preterm Birth

Physician Survey Demonstrates Need for an Approved Vaginal Progesterone Product Juniper is Advancing Its Investigational Progesterone Intravaginal Ring to Treat Women at Risk for Preterm Birth due to Short Cervix BOSTON, Jan. 26, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP) ("J...

Read More

Juniper Pharmaceuticals Unveils Strategic and Product Development Objectives for 2017

Juniper Advancing IVR Pipeline while Actively Pursuing Partnering Opportunities Aligned with Mission to Transform Women's Health BOSTON, Jan. 6, 2017 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company") today announced plans for 2017 that are expected to enab...

Read More

Juniper Pharmaceuticals Announces Poster Presentation at Society for Maternal-Fetal Medicine 2017 Annual Meeting

BOSTON, Jan. 5, 2017 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced that an abstract describing data exploring current practices among U.S. obstetricians to screen, define, and treat a short cervix...

Read More

Juniper Pharmaceuticals Announces Appointment of Jeffrey Young as Chief Financial Officer

BOSTON, Dec. 20, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced the appointment of Jeffrey Young as Chief Financial Officer, Treasurer and Secretary effective January 1, 2017. ...

Read More

Juniper Pharmaceuticals Monetizes U.S. Crinone Royalty Stream with Allergan

- Transaction Provides $11 Million of Non-Dilutive Cash to Juniper - BOSTON, Nov. 15, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced it has entered into an agreement with its partner, Allergan...

Read More

Juniper Pharmaceuticals Reports Third Quarter 2016 Financial Results

-- Conference call at 8:30 a.m. EST today -- BOSTON, Nov. 15, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced financial results for the three- and nine- month periods ended September 30, 2016. ...

Read More

Juniper Pharmaceuticals to Report Third Quarter 2016 Results on November 15, 2016

-- Conference Call Scheduled for 8:30 a.m. EST -- BOSTON, Nov. 14, 2016 /PRNewswire/ -- The management team of Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), will hold a conference call on November 15, 2016, to discuss the financial results for the third quarter and n...

Read More

Juniper Pharmaceuticals to Present at Rodman & Renshaw Global Investment Conference on September 12, 2016

BOSTON, Aug. 31, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), announced today that Alicia Secor, President and Chief Executive Officer, will present at the Rodman & Renshaw 18th Annual Global Investment Conference, sponsored by H.C. Wainwright &a...

Read More

Juniper Pharmaceuticals Reports Results from Phase 2b Clinical Trial of COL-1077 Lidocaine Vaginal Gel in Gynecologic Procedure Pain

BOSTON, Aug. 17, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced that a recently completed Phase 2b clinical trial evaluating its 10% lidocaine bioadhesive vaginal gel, COL-1077, for the reduction o...

Read More

Juniper Pharmaceuticals Reports Second Quarter 2016 Financial Results

PRESS RELEASE Juniper Pharmaceuticals Reports Second Quarter 2016 Financial Results -- Revenues increased 16% year-over-year as product pipeline advances -- -- Conference call at 8:30 a.m. EDT today -- BOSTON, MA – August 4, 2016 -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" ...

Read More

Juniper Pharmaceuticals to Report Second Quarter 2016 Results on August 4, 2016

Conference Call Scheduled for 8:30 a.m. EDT BOSTON, July 26, 2016 /PRNewswire/ -- The management team of women's health therapeutics developer Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), will hold a conference call on August 4, 2016, to discuss the financial result...

Read More

Juniper Pharmaceuticals Appoints Alicia Secor President and Chief Executive Officer

BOSTON, July 20, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced that its Board of Directors has appointed veteran healthcare executive Alicia Secor as its President and CEO, effective August 1, 201...

Read More

Juniper Pharmaceuticals Announces Completion of Enrollment in Phase 2b Clinical Trial of COL-1077 10% Lidocaine Vaginal Gel for Gynecologic Procedure Pain

BOSTON, July 7, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced that it has completed patient enrollment in its Phase 2b clinical trial evaluating its 10% lidocaine bioadhesive vaginal gel, COL-1077...

Read More

Juniper Pharmaceuticals Announces that Merck KGaA, Darmstadt, Germany, has Obtained Regulatory Approval for OneCrinone® in Japan

BOSTON, July 5, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced that for the Japanese market Merck KGaA, Darmstadt, Germany (XETRA: MRK.DE), acting through its biopharma business, has received appro...

Read More

Juniper Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference

BOSTON, June 29, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), announced today that George O. Elston, Chief Financial Officer, will present at the 2nd Annual Cantor Fitzgerald Healthcare Conference in New York, NY on Tuesday, July 12, 2016 at 3:00 p.m...

Read More

Juniper Pharmaceuticals Announces Phase 1 Studies of COL-1077 Lidocaine Vaginal Gel Published in Peer Reviewed Scientific Journal

- Effective vaginal tissue absorption showing safe systemic levels of lidocaine following COL-1077 administration - BOSTON, June 16, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced that the inter...

Read More

Juniper Pharmaceuticals Announces Planned Retirement of CEO Frank Condella

BOSTON, June 2, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced that Frank C. Condella, Jr., plans to retire as the Company's President and Chief Executive Officer ("CEO") later this year.  A search...

Read More

Juniper Pharmaceuticals to Present at Jefferies 2016 Healthcare Conference

BOSTON, May 24, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), announced today that Frank Condella, Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference in New York, NY on Wednesday, June 8, 2016 at 2:30 p.m. EDT.   Ju...

Read More

Juniper Pharmaceuticals Announces Publication of Phase 1 Study Demonstrating Ability of Its Proprietary Intravaginal Ring to Deliver Large Molecules

- Successfully demonstrates ability of an intravaginal ring to deliver leuprolide - - Juniper IVR technology unique among intravaginal rings - BOSTON, May 5, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, ...

Read More

Juniper Pharmaceuticals Reports First Quarter 2016 Financial Results

Product pipeline advanced as revenues increased 45% year-over-year Conference call at 8:30 a.m. EDT today BOSTON, May 4, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced financial results for...

Read More

Juniper Pharmaceuticals to Report First Quarter 2016 Results on May 4, 2016

Conference Call Scheduled for 8:30 a.m. EDT BOSTON, April 26, 2016 /PRNewswire/ -- The management team of women's health therapeutics developer Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), will hold a conference call on May 4, 2016, to discuss financial results of t...

Read More

Juniper Pharmaceuticals Appoints Dr. Herman Weiss as Vice President, Medical Affairs and Clinical Development

- Accomplished Women's Health Executive to Support Development of JNP Proprietary Product Portfolio - BOSTON, March 30, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced that it has appointed Her...

Read More

Juniper Pharmaceuticals Appoints Mary Ann Gray, Ph.D., to Board of Directors

Experienced Corporate Director with Scientific and Financial Background to Chair JNP Audit Committee BOSTON, March 24, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced the appointment of Mary An...

Read More

Juniper Pharmaceuticals Affirms Development Pathway for Oxybutynin Intra-vaginal Ring for Overactive Bladder in Women

JNP-0101 on Track for 2016 Investigational New Drug ("IND") Filing BOSTON, March 21, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (NASDAQ: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today confirmed that it met with representatives of the Food and Drug Admini...

Read More

Juniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2015 Financial Results

Total revenues increased 16% year-over-year, in line with company guidance Conference call at 8:30 a.m. EST today BOSTON, March 10, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced financial ...

Read More

Juniper Pharmaceuticals to Present at ROTH Conference on March 14, 2016

BOSTON, Feb. 29, 2016 /PRNewswire/ -- George Elston, Chief Financial Officer of Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), will present at the 28th Annual ROTH Conference in Dana Point, CA on Monday, March 14, 2016 at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time) in...

Read More

Juniper Pharmaceuticals to Report Fourth Quarter and Year End 2015 Results on March 10, 2016

Conference Call Scheduled for 8:30 a.m. EST BOSTON, Feb. 25, 2016 /PRNewswire/ -- The management team of women's health therapeutics developer Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), will hold a conference call on March 10, 2016, to discuss financial results of...

Read More

Prominent Physicians Join Juniper Pharmaceuticals' Scientific Advisory Board

BOSTON, Jan. 20, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company") announced today the addition of two new Scientific Advisory Board (SAB) members: Linda Giudice, MD, PhD, and Marianne Mann, MD.  "Dr. Linda Giudice and Dr. Marianne Mann bring vast kn...

Read More

Juniper Pharmaceuticals Expands Lead Phase 2b Trial, Submits Pre-IND Meeting Request for its First Intra-vaginal Ring Product, and Adds Four Key Executives

BOSTON, Jan. 11, 2016 /PRNewswire/ -- Building on its recently disclosed refocus on internal product development, Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or "the Company"), today announced the expansion of its lead clinical trial, and the submission of a pre-IND meeting request with t...

Read More

Juniper Pharmaceuticals to Present at 27th Annual Piper Jaffray Healthcare Conference on December 2, 2015

BOSTON, Nov. 18, 2015 /PRNewswire/ -- Frank Condella, CEO of Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or "the Company"), will present at the 27th Annual Piper Jaffray Healthcare Conference as follows: Date: Wednesday, December 2, 2015 Time: 1:5...

Read More

Juniper Pharmaceuticals Adds Three New Products to its Proprietary Pipeline

BOSTON and NEW YORK, Nov. 13, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), announced details of its portfolio pipeline, focused on three new product candidates to treat women's health conditions, at its Investor Day Wednesday. The three new pro...

Read More

Thomson ONE Initially Understates Juniper Pharmaceuticals' Third Quarter 2015 Results in First Call

Corrected results have since been published on First Call BOSTON, Nov. 12, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), today announced that Thomson ONE initially reported understated Juniper results for the third quarter of 2015, including reve...

Read More

Juniper Pharmaceuticals Announces Speakers for November 11, 2015 Investor Day

Live webcast to begin at 10:00 a.m. EST BOSTON, Nov. 10, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health specialty pharmaceutical company, today announced the slate of speakers expected to present at its Investor Day on November 11...

Read More

Juniper Pharmaceuticals Reports Third Quarter 2015 Financial Results

Product revenues and Service revenues up 22% and 35% year-over-year, respectively Investor Day November 11, 2015, at 10:00 a.m. EST BOSTON, Nov. 10, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today ann...

Read More

Juniper Pharmaceuticals to Announce Third Quarter Financial Results on November 10, 2015

BOSTON, Oct. 28, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc., (Nasdaq: JNP) ("the Company") announced today it will report its third quarter 2015 financial results on Tuesday, November 10, 2015, after market close. Management will discuss the results during the Company's Investor Da...

Read More

Juniper Pharmaceuticals to Host Investor Day on November 11, 2015

BOSTON, Oct. 27, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc., (Nasdaq: JNP) ("Juniper" or the "Company") announced today it will hold its 2015 Investor Day from 10:00 a.m. to 12:00 p.m. EST on Wednesday, November 11, 2015. The Investor Day will be held at the Union League Club...

Read More

Juniper Pharmaceuticals Announces Listing on the NASDAQ Global Select Market

BOSTON, Oct. 20, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health specialty pharmaceutical company, announced that its common stock will begin trading on the Nasdaq Global Select Market, effective at market open today. The Company's symb...

Read More

Juniper Pharmaceuticals Reports Second Quarter 2015 Financial Results

- Revenues increased 53% year-over-year to $10.2 million - BOSTON, Aug. 4, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company") a women's health specialty pharmaceutical company, today announced financial results for the three months ended June 30, ...

Read More

Juniper Pharmaceuticals Announces Regulatory Approvals for CRINONE® Progesterone Gel in Nine New EU Countries

BOSTON, July 28, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), a women's health specialty pharmaceutical company, today announced that the regulatory bodies of nine new European Union (EU) countries, including Poland and France, have granted marketing authorization to CRINONE® (p...

Read More

Juniper Pharmaceuticals (JNP) to Discuss Second Quarter 2015 Results on August 4th Conference Call

BOSTON, July 21, 2015 /PRNewswire/ -- The management team of Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("the Company") will hold a conference call on August 4, 2015, to discuss financial results of the second quarter ended June 30, 2015.  The call details are as follows: Date: ...

Read More

Juniper Pharmaceuticals Announces Board Changes

James Geraghty elected Chairman of the Board; Ann Merrifield appointed to Board BOSTON, July 16, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) (the "Company"), a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women's he...

Read More

Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015

BOSTON, June 30, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women's health, today announced that CFO George Elston will present at the Cantor Fitzgerald Inaugural Healthca...

Read More

Juniper Appointed Partner For Groundbreaking Cancer Drug Delivery Platform

NOTTINGHAM, England, June 23, 2015 /PRNewswire/ -- Juniper Pharma Services, a subsidiary of Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), has entered into a long-term collaboration with OxSonics Limited ("OxSonics") to support the development, scale-up, and GMP manufacturing of OxSonics' proprietary ...

Read More

Juniper Pharmaceuticals Announces First Patient Enrolled in Phase II Study of COL-1077 as an Acute-Use Anesthetic for Minimally-Invasive Gynecologic Procedures

BOSTON, June 15, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper"), a specialty pharmaceutical company focused on the development of therapeutics for women's health, announced today the first patient has been enrolled in a Phase II clinical trial of COL-1077, a 10% lidocai...

Read More

Juniper Pharmaceuticals Appoints James A. Geraghty to Board of Directors

Board to Appoint Mr. Geraghty as Chairman Following Annual Meeting of Shareholders BOSTON, May 28, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("the Company") today announced that James A. Geraghty has been appointed a director of the Company and is included in the nominees...

Read More

Juniper Pharmaceuticals to Present at Investor Conference on May 28, 2015

BOSTON, May 26, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("the Company"), a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women's health, today announced that CFO George Elston will present at the Marcum MicroCap Confe...

Read More

Juniper Pharmaceuticals to Present at Jefferies 2015 Global Healthcare Conference on June 4, 2015

BOSTON, May 21, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("the Company"), a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women's health, today announced that CEO Frank Condella will present at the Jefferies 2015 Globa...

Read More

Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results

BOSTON, May 6, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), today announced financial results for the three-month period ended March 31, 2015. First quarter financial highlights include: Total revenues were $8.3 million, an increase of 19% as co...

Read More

Juniper Pharmaceuticals Reschedules Annual General Meeting

BOSTON, April 28, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("the Company"), a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women's health, has rescheduled its 2015 Annual General Meeting of Shareholders from June 2, 2...

Read More

Juniper Pharmaceuticals (JNP) to Discuss First Quarter 2015 Results on May 6th Conference Call

BOSTON, April 23, 2015 /PRNewswire/ -- The management team at Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("the Company"), will hold a conference call on May 6, 2015, to discuss financial results for the first quarter ended March 31, 2015.  The call details are as follows: Date: ...

Read More

Juniper Pharmaceuticals Announces Formation of Scientific Advisory Board

BOSTON, April 22, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("the Company"), a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women's health, today announced the creation of a Scientific Advisory Board ("SAB") comprised ...

Read More

Columbia Laboratories Begins Trading as Juniper Pharmaceuticals (JNP)

-- Company Updates on Q1 Revenue -- BOSTON, April 13, 2015 /PRNewswire/ -- Effective this morning, Columbia Laboratories, Inc. is now Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("the Company"), and its Nottingham, UK based subsidiary Molecular Profiles, Ltd., is now Juniper...

Read More

Columbia Laboratories, Inc. to Become Juniper Pharmaceuticals, Inc.

- Company to Begin Trading as "JNP" on April 13, 2015 - - Company Updates on COL-1077 - BOSTON, April 2, 2015 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) (the "Company"), today announced that it will adopt Juniper Pharmaceuticals, Inc. as its new corporate brand. The name chan...

Read More

Columbia Laboratories Acquires Exclusive Worldwide License to a Novel Segmented Intra-vaginal Ring Delivery Technology

Co-Inventors Robert Langer, Sc.D. and William Crowley, M.D. join as Strategic Advisors to Columbia BOSTON, March 30, 2015 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"), a specialty pharmaceutical company focused on the development of therapeutics for w...

Read More

Columbia Laboratories Reports Fourth Quarter and Full-Year 2014 Financial Results

BOSTON, March 18, 2015 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or the "Company"), today announced financial results for the three- and twelve-month periods ended December 31, 2014.  "The 11% growth in our 2014 full year revenues was driven in large part by a full y...

Read More

Federal Appeals Court Affirms Dismissal of Class Action Lawsuit

BOSTON, March 12, 2015 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"), a specialty pharmaceutical company focused on the development of pharmaceuticals for women's health, announced today that the United States Court of Appeals for the Third Circuit affirmed...

Read More

Columbia Laboratories to Discuss Fourth Quarter and Full Year 2014 Financial Results on March 18th Conference Call

BOSTON, March 10, 2015 /PRNewswire/ -- The management team at Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on March 18, 2015, to discuss financial results for the fourth quarter and full year ended December 31, 2014.  The call details are as follows: Date: ...

Read More

Columbia Laboratories to Present at the 27th Annual ROTH Conference

BOSTON, March 3, 2015 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"), a specialty pharmaceutical company focused on pharmaceuticals for women's health, today announced that it will present at the 27th Annual ROTH Conference, which will take place from March ...

Read More

Columbia Laboratories to Initiate a Phase II Clinical Trial for COL-1077, Lidocaine Bioadhesive 10% Gel, in the Second Quarter of 2015

BOSTON, Feb. 26, 2015 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"), a specialty pharmaceutical company focused on the development of pharmaceuticals for women's health, plans to initiate a Phase II clinical trial for COL-1077, a lidocaine bioadhesive 10% g...

Read More

Columbia Laboratories Announces Date of 2015 Annual Meeting of Stockholders

BOSTON, Feb. 5, 2015 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"), a specialty pharmaceutical company focused on pharmaceuticals for women's health, today announced that its annual meeting of stockholders will be held on June 2, 2015.  The Company will ann...

Read More

Columbia Laboratories to Present at the 17th Annual BIO CEO & Investor Conference

BOSTON, Feb. 2, 2015 /PRNewswire/ --Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"), a specialty pharmaceutical company focused on pharmaceuticals for women's health, today announced that it will present at the upcoming 17th Annual BIO CEO & Investor Conference, to be he...

Read More

Columbia Laboratories Announces Search For New Board Member, Impending Retirement of Chairman Stephen G. Kasnet; Amendment to Increase Permissible Ownership Levels Under Shareholder Rights Plan

BOSTON, Jan. 29, 2015 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"), a specialty pharmaceutical company focused on pharmaceuticals for women's health, today announced that the Company's Chairman, Stephen G. Kasnet, has informed the Company that he does not ...

Read More

Columbia Laboratories Appoints Bridget A. Martell as CMO

BOSTON, Jan. 6, 2015 -- Columbia Laboratories, Inc.(Nasdaq: CBRX) a specialty pharmaceutical company focused on pharmaceuticals for women's health, today announced the appointment of Dr. Bridget A. Martell, 49, to the newly created position of Chief Medical Officer, effective immediately. The appoin...

Read More

Molecular Profiles To Launch US Strategic Alliance At AAPS

NOTTINGHAM, United Kingdom, Oct. 30, 2014 /PRNewswire/ -- Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq: CBRX) and Maryland-based Xceleron have announced a collaboration to assist drug developers with improved efficiency during clinical development that will be launch...

Read More

Columbia Laboratories Reports Third Quarter 2014 Financial Results

BOSTON, Oct. 28, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company") today announced financial results for the three and nine-month periods ended September 30, 2014. Third Quarter Financial HighlightsTotal revenues of $11.5 million, including a $2.2 million ...

Read More

Columbia Laboratories to Discuss Third Quarter 2014 Financial Results on October 28th Conference Call

BOSTON, Oct. 14, 2014 /PRNewswire/ -- The management team at Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on October 28th, 2014, to discuss financial results for the third quarter ended September 30, 2014. The call details are as follows:Date:Tuesday, October 28, 2014Time:8...

Read More

Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI

BOSTON and NOTTINGHAM, England, Oct. 1, 2014 /PRNewswire/ -- Columbia Laboratories, Inc., (Nasdaq: CBRX) today announced that its subsidiary, Molecular Profiles Ltd., is set to unveil the ROADMAP to Clinical Trials platform at the annual CPhI/ICSE Worldwide event in Paris next week, which aims to su...

Read More

Columbia Laboratories Announces Appointment of New Chief Financial Officer

BOSTON, Sept. 24, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"), a provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry, today announced that the Board has ...

Read More

Columbia Laboratories Announces Completion of CRINONE License Renewal

BOSTON, Sept. 8, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"), a provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry, today announced that Merck Serono ha...

Read More

Columbia Laboratories to participate in the Rodman & Renshaw 16th Annual Global Investment Conference

BOSTON, Aug. 27, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"), a provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry, today announced that it will partici...

Read More

Columbia Laboratories Announces Sale Of IP And Technology For Legatrin P.M. To Lil' Drug Store Products

BOSTON, Aug. 6, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that Lil' Drug Store Products exercised its option to purchase the Intellectual Property Rights and Technology related to Legatrin P.M. Columbia licensed this product to Lil' Drug Store Products approxima...

Read More

Columbia Laboratories' Subsidiary, Molecular Profiles, Strikes Alliance With Xenogesis

BOSTON and NOTTINGHAM, England, July 31, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced that its subsidiary, Molecular Profiles Ltd., and XenoGesis Ltd., have announced a collaboration that will support pharmaceutical and biotech drug developers during the pre-clinic...

Read More

Columbia Laboratories Reports Second Quarter 2014 Financial Results

BOSTON, July 31, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company") today announced financial results for the three and six-month periods ended June 30, 2014. "Second quarter results benefited from the contribution of the Molecular Profiles services busines...

Read More

Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call

BOSTON, July 23, 2014 /PRNewswire/ -- The management team at Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on July 31, 2014, to discuss financial results for the second quarter ended June 30, 2014. The call details are as follows:Date:Thursday, July 31, 2014Time:8:30 am EDTD...

Read More

Columbia Laboratories Expands its Intellectual Property Portfolio Following Receipt of U.S. Patent

BOSTON, July 17, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"), a provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry, today announced that it has expanded...

Read More

Columbia Laboratories Added to the Russell Microcap Index

BOSTON, June 26, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"), a provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry, today announced that it has been add...

Read More

Columbia Laboratories Reports First Quarter 2014 Financial Results

BOSTON, April 29, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company") today announced financial results for the three-month period ended March 31, 2014. First Quarter 2014 Financial Highlights Total revenues grew 15% to $7.2 million compared to $6.3...

Read More

Columbia Laboratories to Discuss First Quarter 2014 Financial Results on April 29th Conference Call

BOSTON, April 17, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on April 29, 2014, to discuss financial results of the first quarter ended March 31, 2014. Frank Condella, President and Chief Executive Officer, and Jonathan Lloyd Jones, Vice President and...

Read More

Molecular Profiles Strengthens US Presence To Drive Growth

NOTTINGHAM, England, April 15, 2014 /PRNewswire/ -- Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq: CBRX), is set to increase awareness and uptake of its pharmaceutical development services in the North American market following the appointment of a new head of US sale...

Read More

Molecular Profiles Expands Technology With GMP Hot Melt Extrusion

NOTTINGHAM, England, April 8, 2014 /PRNewswire/ -- Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq: CBRX) has completed a significant investment into additional equipment as part of a wider project focusing on enabling technologies that facilitate processing of difficul...

Read More

Columbia Laboratories Repurchases 1.4 Million Shares of Common Stock from Actavis

BOSTON, March 7, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that the Company has repurchased 1.4 million shares of its common stock, par value $0.01 per share, from Coventry Acquisition, LLC, a subsidiary of Actavis Inc. (Actavis), at $6.08 per share, which repre...

Read More

Columbia Laboratories Reports Fourth Quarter and Full Year 2013 Financial Results

BOSTON, March 5, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced financial results of the three- and twelve-month periods ended December 31, 2013.Financial highlights for the fourth quarter of 2013: Total net revenues grew 10% to $7.8 million compared to $7.1 million ...

Read More

Columbia Laboratories Announces Board Changes

BOSTON, Mar. 3, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that Donald H. Hunter, an executive and technology consultant with over 25 years of public company experience, has been appointed to its Board of Directors. Mr. Hunter qualifies as a financial expert unde...

Read More

Columbia Laboratories to Discuss Fourth Quarter and Year End 2013 Financial Results on March 5 Conference Call

BOSTON, Feb. 26, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on March 5, 2014, to discuss financial results of the fourth quarter and fiscal year ended December 31, 2013. Frank Condella, President and Chief Executive Officer, and Jonathan Lloyd Jones, ...

Read More

Columbia Laboratories, Inc. Announces Restatement of Previously- Issued Unaudited Interim Consolidated Financial Statements for the Three- and Nine-Month Periods Ended September 30, 2013

BOSTON, Feb. 19, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced a restatement of its previously-issued unaudited interim consolidated financial statements for the three- and nine-month periods ended September 30, 2013 due to a calculation error related to its common ...

Read More

Columbia Laboratories to Present February 11th at BIO CEO & Investor Conference

BOSTON, Feb. 4, 2014 /PRNewswire/ -- Frank Condella, President and Chief Executive Officer of Columbia Laboratories Inc. (Nasdaq: CBRX) will present at the 16th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference. The presentation is scheduled as follows: Date:Tuesday, Feb...

Read More

Columbia Laboratories Announces Preliminary Fourth Quarter and Year-End 2013 Results

BOSTON, Jan. 9, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced preliminary, unaudited financial results of the fourth quarter and year ended December 31, 2013. For the fourth quarter of 2013, the Company expects to report: Total revenues in the range of $7.4 to $8.0 ...

Read More

Molecular Profiles Joins Leading Consortium To Drive Paediatric Formulation Development

NOTTINGHAM, England, Dec. 19, 2013 /PRNewswire/ --A collaborative pharmaceutical project focused on improving the pathway for developing paediatric formulations has been given the go-ahead after successfully securing an innovation grant.The UK-wide consortium, led by Astra Zeneca, received a £660k g...

Read More

Columbia Laboratories to receive One-time Payment from Actavis for CRINONE U.S. Manufacturing Rights

BOSTON, Nov. 14, 2013 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) has entered into an agreement with Actavis, Inc. ("Actavis") for early termination of the companies' current exclusive Supply Agreement for CRINONE® (progesterone gel). The exclusive Supply Agreement, which would have o...

Read More

Columbia Laboratories Reports Third Quarter 2013 Financial Results

BOSTON, Nov. 7, 2013 (GLOBE NEWSWIRE) -- Columbia Laboratories, Inc. (Nasdaq:CBRX) today announced financial results for the three months ended September 30, 2013. Highlights include:Revenues of $7.1 million, up 7% from Q3 of 2012Non-GAAP adjusted diluted net income per share of $0.20, excluding acq...

Read More

Columbia Laboratories to Discuss Third Quarter 2013 Financial Results on November 7 Conference Call

BOSTON, Oct. 24, 2013 (GLOBE NEWSWIRE) -- Columbia Laboratories, Inc. (Nasdaq:CBRX) will hold a conference call on November 7, 2013, to discuss financial results of the third quarter ended September 30, 2013. Frank Condella, President and Chief Executive Officer, and Jonathan Lloyd Jones, Vice Presi...

Read More

Amended Class Action Lawsuit against Columbia Laboratories Dismissed without Prejudice

Columbia Laboratories, Inc. (Nasdaq:CBRX) announced today that the previously disclosed Consolidated Second Amended Class Action Complaint to the putative class action lawsuit filed against the Company, Actavis, Inc. and certain officers of both companies (the “Defendants”) in the United States Dist...

Read More

Molecular Profiles Selected to Develop Topical & Oral Psoriasis Products for Telormedix

Pharmaceutical formulation development and manufacturing services provider Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq:CBRX) has been selected as the formulation development partner for a major pan-European collaborative project. The UK-based company has been chos...

Read More

Columbia Laboratories Expands Board of Directors

Columbia Laboratories, Inc. (Nasdaq:CBRX) today announced that its Board of Directors has appointed three experienced healthcare executives with over 65 years collective industry experience to its Board of Directors, effective immediately. Dr. Frank Armstrong and Dr. Nikin Patel have been appointed ...

Read More

Columbia Laboratories Acquires Molecular Profiles Ltd., a U.K.-Based Provider of Pharmaceutical Formulation Development and Manufacturing Services

Columbia Laboratories Inc. (NasdaqCM:CBRX) [“Columbia”, the “Company”] has acquired Molecular Profiles Ltd. [“Molecular Profiles”], a privately-held, cash-flow positive, U.K.-based pharmaceutical development services company, for total consideration of approximately $25.0 million comprising $16.7 mi...

Read More

Columbia Laboratories Regains Compliance with Nasdaq Listing Standards

Columbia Laboratories, Inc. (NasdaqCM:CBRX) received notice on August 23, 2012, from the Nasdaq Stock Market that the Company has regained compliance with the Nasdaq Stock Market minimum bid price requirement as set forth in Listing Rule 5550(a)(2). The notice stated that the closing bid price of th...

Read More

Columbia Laboratories Announces One-for-Eight Reverse Stock Split

Columbia Laboratories, Inc. (“Columbia” or the “Company”) (NasdaqCM: CBRX) announced a 1-for-8 reverse split of its Common Stock, par value $0.01 per share (the “Common Stock”), effective tomorrow, August 9, 2013 (the “Effective Date”). The reverse stock split was approved by the Company’s stockhold...

Read More

Columbia Laboratories Reports Second Quarter 2013 Financial Results

Columbia Laboratories, Inc. (“Columbia” or the “Company”) (NasdaqCM: CBRX) announced a 1-for-8 reverse split of its Common Stock, par value $0.01 per share (the “Common Stock”), effective tomorrow, August 9, 2013 (the “Effective Date”). The reverse stock split was approved by the Company’s stockhold...

Read More

Columbia Laboratories’ Board Approves 1-for-8 Reverse Stock Split

Columbia Laboratories, Inc. (“Columbia” or the “Company”) (NasdaqCM: CBRX) announced today that its Board of Directors (the “Board”) has set a ratio of 1-for-8 for its previously approved reverse stock split of its common stock, and an anticipated effective date for the reverse stock split of the la...

Read More

Columbia Laboratories to Discuss Second Quarter 2013 Financial Results on August 7 Conference Call

Columbia Laboratories, Inc. (NasdaqCM: CBRX) will hold a conference call on August 7, 2013, to discuss financial results of the second quarter ended June 30, 2013. Frank Condella, President and Chief Executive Officer, and Jonathan Lloyd Jones, Vice President and Chief Financial Officer of Columbia ...

Read More

Plaintiffs Amend Previously Dismissed Class Action Lawsuit against Columbia Laboratories

Columbia Laboratories, Inc. (NasdaqCM: CBRX) announced today that plaintiffs in the putative class action lawsuit filed against the Company, Actavis, Inc. and certain officers of both companies (the “Defendants”) in the United States District Court, District of New Jersey, entitled In re Columbia La...

Read More

Columbia Laboratories Announces Completion of Corporate Relocation

Columbia Laboratories, Inc. (NasdaqCM: CBRX) announced today that the Company has completed the relocation of its corporate headquarters from Livingston, New Jersey, to Boston, Massachusetts. Columbia’s new corporate address is 4 Liberty Square, Boston, MA 02109. About Columbia Laboratories Columbi...

Read More

Class Action Lawsuit against Columbia Laboratories Dismissed without Prejudice

Columbia Laboratories, Inc. (NasdaqCM: CBRX) announced today that the previously disclosed putative class action lawsuit filed against the Company, Actavis, Inc. and certain officers of both companies (the “Defendants”) in the United States District Court, District of New Jersey, entitled In re Colu...

Read More

Columbia Laboratories Reports First Quarter 2013 Financial Results

Columbia Laboratories, Inc. (NasdaqCM: CBRX) today reported financial results for the three-month period ended March 31, 2013. Highlights of the first quarter include: Total net revenues increased 65% to $6.3 million in the first quarter of 2013, compared to $3.8 million in the first quarter of 20...

Read More

Columbia Laboratories to Discuss First Quarter 2013 Financial Results on May 9 Conference Call

Columbia Laboratories Inc. (Nasdaq: CBRX) will hold a conference call on May 9, 2013, to discuss financial results of the first quarter ended March 31, 2013. Frank Condella, President and Chief Executive Officer, and Jonathan Lloyd Jones, Vice President and Chief Financial Officer of Columbia Labora...

Read More

Columbia Laboratories Extends Agreement with Merck Serono for CRINONE Ex-U.S. into 2020

Livingston, NJ -- April 9, 2013 -- Columbia Laboratories, Inc. (Nasdaq: CBRX) has amended its license and supply agreement with Merck Serono, a division of Merck KGaA (XETRA: MRK.DE), Darmstadt, Germany, for CRINONE® (progesterone gel) through May 2020, representing an extension of five years beyond...

Read More

Columbia Laboratories Reports Fourth Quarter and Year-End 2012 Financial Results

Columbia Laboratories, Inc. (Nasdaq: CBRX) today reported financial results for the three- and twelve-month periods ended December 31, 2012. Fourth Quarter Financial Highlights Total net revenues increased 11% to $7.1 million in the fourth quarter of 2012, compared to $6.4 million in the fourth qua...

Read More

Columbia Laboratories Extends Stockholder Rights Plan to Preserve Use of Net Operating Losses under Section 382

Columbia Laboratories, Inc. (Nasdaq: CBRX) (the “Company”) today announced that its Board of Directors on March 1, 2013 adopted an amendment to its Stockholder Rights Plan (the "Rights Plan"), originally adopted on March 12, 2002, to extend the expiration date of the Rights Plan from July 3, 2013 to...

Read More

Columbia Laboratories to Discuss Fourth Quarter and Year-End 2012 Financial Results on March 14 Conference Call

Columbia Laboratories Inc. (Nasdaq: CBRX) will hold a conference call on March 14, 2013, to discuss financial results of the fourth quarter and year ended December 31, 2012. Frank Condella, president and chief executive officer, and Jonathan Lloyd Jones, vice president, chief financial officer, trea...

Read More

Columbia Laboratories to Present March 6th at Cowen and Company Health Care Conference

Columbia Laboratories Inc. (Nasdaq: CBRX) announced today that Frank Condella, President and Chief Executive Officer will present at the Cowen and Company 33rd Annual Health Care conference. The presentation is scheduled as follows: Date: Wednesday, March 6, 2013 Time: 11:20 a.m. Eastern Ti...

Read More

Jonathan B. Lloyd Jones Appointed CFO of Columbia Laboratories

Columbia Laboratories Inc. (Nasdaq: CBRX) today announced the appointment of Jonathan B. Lloyd Jones, ACA, MBA, as Vice President, Finance, Chief Financial Officer, Treasurer and Secretary, effective January 21. He will be based at Columbia’s corporate headquarters, which will be relocated to the ar...

Read More